Patent intelligence · US
US 12329805
Dosage forms of tissue kallikrein 1
Dosage forms of tissue kallikrein 1
Patent details — US 12329805
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 17, 2025
- Expiration
- Jun 12, 2045
- Applicant
- DiaMedica Inc.
- Claims
- 18
- CPC classes
- A61K, A61K38/4853, A61K45/06, A61K9/0019
Quick answer
US 12329805 (Dosage forms of tissue kallikrein 1) is held by DiaMedica Inc.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DiaMedica Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K38/4853, A61K45/06, A61K9/0019, A61P, A61P9/10
More from DiaMedica Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11857608
Dosage forms of tissue kallikrein 1
granted -
US 11725043
Ulinastatin polypeptides
granted -
US 9839678
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 9616015
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
granted -
US 9364521
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 8673964
Use of drug combinations for treating insulin resistance
granted -
US 8501695
Tissue kallikrein for the treatment of diseases associated with amyloid protein
granted
Frequently asked questions
What is US patent 12329805?
US 12329805 (Dosage forms of tissue kallikrein 1) is held by DiaMedica Inc.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12329805?
DiaMedica Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12329805 expire?
Our index shows an expiration date of Jun 12, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.